BIOL logo

BIOLASE, Inc. (BIOL) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

BIOLASE, Inc. (BIOL), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 47/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
47/100 AI Puanı

BIOLASE, Inc. (BIOL) Sağlık ve Boru Hattı Genel Bakışı

CEOJohn R. Beaver
Çalışanlar157
MerkezFoothill Ranch, US
Halka Arz Yılı1992
SektörHealthcare

BIOLASE, Inc. focuses on dental laser systems, offering Waterlase and diode laser technologies for a range of dental procedures. With a global presence and a direct sales force, BIOLASE competes in the dental device market, emphasizing minimally invasive solutions for dentists and specialists.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

BIOLASE, Inc. operates in the dental laser market, a segment driven by the increasing demand for minimally invasive dental procedures. The company's innovative Waterlase and diode laser systems provide a competitive edge. Key value drivers include expanding the installed base of laser systems and increasing recurring revenue from consumables and accessories. Growth catalysts include ongoing advancements in laser technology and expanding the applications of dental lasers. The company's gross margin stands at 34.0%. Potential risks include competition from established dental equipment manufacturers and the need for continuous innovation to maintain market share. The company's market capitalization is $0.00B, and it has a negative P/E ratio.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • BIOLASE operates with 157 employees, indicating a relatively lean operational structure.
  • The company's gross margin is 34.0%, reflecting its ability to generate revenue above the cost of goods sold.
  • BIOLASE has a negative profit margin of -42.0%, signaling challenges in achieving overall profitability.
  • The company's beta is 0.68, suggesting lower volatility compared to the broader market.
  • BIOLASE does not currently offer a dividend, which is common for growth-oriented companies in the medical device sector.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative laser technology for minimally invasive dental procedures.
  • Established presence in the dental laser market.
  • Direct sales force and distributor network.
  • Comprehensive product portfolio including laser systems and consumables.

Zayıflıklar

  • Negative profit margin indicating financial challenges.
  • Limited market capitalization.
  • Dependence on a niche market segment.
  • Intense competition from established dental equipment manufacturers.

Katalizörler

  • Upcoming: Potential FDA approvals for new laser applications could expand market reach.
  • Ongoing: Increasing adoption of minimally invasive dental procedures drives demand for BIOLASE's products.
  • Ongoing: Strategic partnerships with dental clinics and universities can enhance market penetration.

Riskler

  • Potential: Competition from established dental equipment manufacturers could erode market share.
  • Potential: Economic downturn may impact dental spending and demand for BIOLASE's products.
  • Ongoing: Regulatory changes in the dental industry could affect product approvals and market access.

Büyüme Fırsatları

  • Expanding the installed base of Waterlase and diode laser systems represents a significant growth opportunity for BIOLASE. By increasing the number of dental practitioners using its laser systems, the company can drive revenue growth and establish a stronger market presence. This expansion can be achieved through targeted marketing campaigns, strategic partnerships with dental clinics, and participation in industry conferences. The market for dental laser systems is projected to grow as more dentists adopt minimally invasive techniques, presenting a favorable environment for BIOLASE's growth.
  • Increasing recurring revenue from consumables and accessories is another key growth driver for BIOLASE. As the installed base of laser systems expands, the demand for consumable products such as flexible fibers, hand pieces, and teeth whitening gel kits will also increase. By offering high-quality consumables and accessories, BIOLASE can generate a steady stream of recurring revenue and enhance customer loyalty. This strategy aligns with the company's focus on providing comprehensive solutions for dental practitioners, fostering long-term relationships and driving sustainable growth.
  • Developing new applications for dental lasers represents a significant growth opportunity for BIOLASE. By expanding the range of procedures that can be performed using its laser systems, the company can attract new customers and increase the utilization of its existing products. This can be achieved through ongoing research and development efforts, clinical trials, and collaborations with dental professionals. The potential applications for dental lasers are vast, ranging from cosmetic dentistry to surgical procedures, offering ample opportunities for BIOLASE to innovate and expand its market reach.
  • Expanding into new geographic markets is a strategic growth opportunity for BIOLASE. By entering new regions, the company can diversify its revenue streams and reduce its reliance on existing markets. This expansion can be achieved through strategic partnerships with local distributors, participation in international dental conferences, and targeted marketing campaigns. The global market for dental laser systems is growing, presenting a favorable environment for BIOLASE to expand its international presence and capitalize on new opportunities.
  • Collaborating with dental schools and universities to integrate BIOLASE's laser systems into dental education programs can drive long-term growth. By training future dentists on its products, the company can create a pipeline of potential customers and establish a strong brand presence within the dental community. This can be achieved through partnerships with dental schools, offering training programs, and providing access to its laser systems for educational purposes. This initiative will help BIOLASE foster brand loyalty and drive future sales as these students enter professional practice.

Fırsatlar

  • Expanding the installed base of laser systems.
  • Increasing recurring revenue from consumables and accessories.
  • Developing new applications for dental lasers.
  • Expanding into new geographic markets.

Tehditler

  • Competition from established dental equipment manufacturers.
  • Technological advancements by competitors.
  • Regulatory changes affecting the dental industry.
  • Economic downturn impacting dental spending.

Rekabet Avantajları

  • Proprietary laser technology with patents.
  • Established brand recognition in the dental laser market.
  • Direct sales force and distributor network providing market access.
  • Focus on minimally invasive dental procedures.

BIOL Hakkında

BIOLASE, Inc., established in 1984 and headquartered in Foothill Ranch, California, specializes in the development, manufacture, and marketing of laser systems for the dental industry. The company's core offerings include the Waterlase all-tissue dental laser systems, designed for cutting both soft and hard tissues, and diode soft-tissue laser systems used in soft tissue procedures, pain therapy, teeth whitening, and cosmetic applications. Additionally, BIOLASE offers the Epic Hygiene laser, which is used to manage non-surgical periodontitis and enhance clinical production. These laser systems enable dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a variety of minimally invasive dental procedures, ranging from cosmetic and restorative to complex surgical applications. BIOLASE also provides consumable products and accessories for its laser systems, including flexible fibers, hand pieces, and teeth whitening gel kits. The company distributes its products through a direct field sales force and a network of distributors, serving dental practitioners and their patients both in the United States and internationally. Formerly known as BIOLASE Technology, Inc., the company rebranded to BIOLASE, Inc. in 2012, marking a strategic shift in its corporate identity and market focus.

Ne Yaparlar

  • Develops and manufactures Waterlase all-tissue dental laser systems.
  • Offers diode soft-tissue laser systems for various dental procedures.
  • Provides Epic Hygiene laser for managing non-surgical periodontitis.
  • Sells consumable products and accessories for its laser systems.
  • Markets flexible fibers and hand pieces for dental lasers.
  • Offers teeth whitening gel kits.
  • Distributes products through a field sales force and distributor network.

İş Modeli

  • Sells dental laser systems to dental practitioners and specialists.
  • Generates revenue from consumable products and accessories.
  • Provides training and support services for its laser systems.

Sektör Bağlamı

BIOLASE operates within the medical device industry, specifically focusing on dental laser systems. The dental device market is characterized by technological advancements and a growing demand for minimally invasive procedures. Competition includes established dental equipment manufacturers and specialized laser companies. The industry is driven by factors such as an aging population, increasing awareness of oral health, and advancements in dental technology. BIOLASE's focus on laser-based solutions positions it within a niche segment of this broader market.

Kilit Müşteriler

  • Dentists
  • Periodontists
  • Endodontists
  • Oral Surgeons
  • Dental Hygienists
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

BIOLASE, Inc. (BIOL) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

BIOL için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

BIOL için Wall Street fiyat hedefi analizi.

MoonshotScore

47/100

Bu puan ne anlama geliyor?

MoonshotScore, BIOL'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: John R. Beaver

CEO

John R. Beaver serves as the CEO of BIOLASE, Inc. His professional background includes extensive experience in managing and leading technology-driven companies. He is responsible for overseeing the strategic direction, operational execution, and financial performance of the company. His leadership aims to drive innovation, expand market reach, and enhance shareholder value. Further details regarding his specific career history and educational background are not available.

Sicil: Under John R. Beaver's leadership, BIOLASE has focused on expanding its product portfolio and market presence in the dental laser industry. Key initiatives include enhancing the company's sales and marketing efforts, driving innovation in laser technology, and strengthening relationships with dental professionals. Specific achievements and milestones under his tenure are not available.

BIOL Healthcare Hisse Senedi SSS

BIOL için değerlendirilmesi gereken temel faktörler nelerdir?

BIOLASE, Inc. (BIOL) şu anda yapay zeka skoru 47/100, düşük puanı gösteriyor. Temel güçlü yan: Innovative laser technology for minimally invasive dental procedures.. İzlenmesi gereken birincil risk: Potential: Competition from established dental equipment manufacturers could erode market share.. Bu bir finansal tavsiye değildir.

BIOL MoonshotScore'u nedir?

BIOL şu anda MoonshotScore'da 47/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

BIOL verileri ne sıklıkla güncellenir?

BIOL fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler BIOL hakkında ne diyor?

BIOL için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

BIOL'a yatırım yapmanın riskleri nelerdir?

BIOL için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established dental equipment manufacturers could erode market share.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

BIOL'ın P/E oranı nedir?

BIOL için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için BIOL'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

BIOL aşırı değerli mi, yoksa düşük değerli mi?

BIOLASE, Inc. (BIOL)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

BIOL'ın temettü verimi nedir?

BIOLASE, Inc. (BIOL) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on the most recent available information.
  • AI analysis is pending, and analyst opinions may vary.
  • Market conditions and competitive landscape are subject to change.
Veri Kaynakları

Popüler Hisseler